Global Pulmonary Drug Delivery Market, By Formulations (Type, Device Type, Accessories), Canister Type (Plain Canister, Coated Canister), Application (Chronic Obstructive Pulmonary Disease (COPD), Asthma, Cystic Fibrosis, Allergic Rhinitis, Other), End-User (Hospitals and Clinics, Home Care Settings) – Industry Trends and Forecast to 2030.
Pulmonary Drug Delivery Market Analysis and Size
The primary goal of the drug delivery route, known as pulmonary drug delivery, is to deposit inhaled pharmacological agents in lower airways with devices that assist with inhaling drug formulations through the mouth. They are extensively used in various end-user industries, including hospitals, clinics, and home care settings. Numerous devices are used for respiratory delivery, including nebulizers, metered-dose inhalers, and dry powder inhalers. Inhaled beta-agonists, corticosteroids, and anticholinergic medications are delivered through the lungs to treat asthma and chronic obstructive pulmonary disease (COPD). The pulmonary administration route has several advantages. The medication is administered right to the disease site to treat respiratory diseases.
Data Bridge Market Research analyses that the pulmonary drug delivery market, valued at USD 47.85 billion in 2022, will reach USD 72.88 billion by 2030, growing at a CAGR of 5.4% during the forecast period of 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Pulmonary Drug Delivery Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Formulations (Type, Device Type, Accessories), Canister Type (Plain Canister, Coated Canister), Application (Chronic Obstructive Pulmonary Disease (COPD), Asthma, Cystic Fibrosis, Allergic Rhinitis, Other), End-User (Hospitals and Clinics, Home Care Settings)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd (Switzerland), MannKind Corporation (U.S.), OMRON Healthcare, Inc. (Japan), Mylan N.V (U.S.), 3M (U.S.), Koninklijke Philips N.V. (Netherlands), Merck & Co., Inc., (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sunovion Pharmaceuticals Inc. (U.S.), PARI GmbH (Germany), Jabil Inc. (U.S.), AstraZeneca (U.K.), Boehringer Ingelheim International GmbH. (Germany), GSK plc. (U.K.), Novartis AG (Switzerland), Aerogen Pharma (Irland), Briggs Healthcare (U.S.), HAAG-STREIT GROUP (Switzerland), Janssen Global Services, LLC (U.S.), AptarGroup, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Directing the drug to the intended site is referred to as "targeted drug delivery." A targeted drug delivery system called pulmonary drug delivery requires the drug moiety toward the lower respiratory tract. A device used to administer medications to the body via the pulmonary route is called a pulmonary drug delivery system. The inhalation route offers a superior alternative to oral administration for treating asthma and chronic obstructive pulmonary disease. Instantaneous action from pulmonary drug delivery relieves acute bronchitis and asthmatic attacks. For pulmonary drug delivery, aerosols are specially made-devices.
Pulmonary Drug Delivery Market Dynamics
Drivers
- Rising prevalence of severe respiratory surges the demand
The rising prevalence of severe respiratory diseases like cystic fibrosis and chronic obstructive pulmonary disease is driving the growth of the pulmonary drug delivery market. Additionally, the growing demand for minimally invasive and effective treatments and the rising trend of pulmonary drug delivery due to features of a large porous area, thin absorbent mucosal membrane, and efficient blood supply will boost the market growth. Additionally, the rising smoking prevalence can impact respiratory, further accelerating the market's overall growth.
- The prevalence of pulmonary diseases drives the market
An increase in air pollution in the prevalence of pulmonary diseases such as asthma and chronic obstructive pulmonary disease, has showcase growing number of hospitals and diagnostic facilities, a surge in funding from private and public organizations for the treatment of pulmonary diseases, and an increase in public awareness of pulmonary health are the main factors driving the global market for pulmonary drug delivery systems. The World Health Organization reports that 9 out of 10 people breathe air that contains high levels of pollutants, and estimates indicate that in 2018, ambient (outdoor) and household air pollution will be responsible for an alarming 7 million annual deaths.
Opportunities
- Online shopping, as a result of technological development, fuels the market
Emerging markets and online channels are anticipated to expand and experience technological advancements to open up profitable market opportunities. The trend and demand for online shopping are growing due to its comfort, adaptability, and convenience, boosting the revenue generated by this market. Customers can also get discounts when they shop online. Additionally, the sum of these factors will increase demand for online pharmacies, and the advantages such as low cost and quick preparation and administration times, will persuade users to use these inhalers more frequently. Thus, with the technological advancements that have made dry powder inhalers a preferred medical device for treating various respiratory disorders, the use of these products has increased. Thus it will help in the expansion of the market.
- Hospital pharmacies are more trustable by people, which creates expansion in market
The segment of hospital pharmacies held the most significant percentage of the patient-determined disease steps and is anticipated to maintain that position going forward. Patients favor hospital pharmacies because they offer comprehensive medical care, quick reimbursements, and insurance policies. In addition, a rise in hospitalizations is anticipated to spur this market's expansion
Restraints/Challenges
- Lack of knowledge prevents the market from expansion
Drugs' expiring patents and general ignorance could obstruct the market's expansion. The general public's lack of knowledge about nasal drug delivery methods hinders market expansion. The technique for administering the doses must be explained to the patients. This limits the market's expansion for pulmonary drug delivery systems. The overall market revenue is hindered during the forecast period by inadequate training, a lack of understanding, and improper usage.
- High costs and strict regulations may limit the market
The market is growing due to numerous healthcare foundations and government initiatives for treating pulmonary diseases. However, the market is constrained by the high costs associated with pulmonary drug delivery system devices. The potential for implanted device failures and inadequate reimbursement in developed economies hampers the market's expansion. The growth of the overall market is also hampered by the strict regulatory policies for procedures and the high cost of treatment.
This pulmonary drug delivery market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pulmonary drug delivery market contact Data Bridge Market Research for an analyst brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2022, Subintro's acquisition by RIGImmune gave it access to cutting-edge topical delivery systems. With this agreement, the biotech is better positioned to advance the creation of cutting-edge RNA therapies and vaccine adjuvants for local mucosal delivery.
- In 2022, Orbital Dry Powder Inhaler (DPI) worldwide license was acquired by Aptar Pharma. This acquisition will enable Aptar Pharma to meet the rising demand for easy and secure high-dose lung treatment administration.
- In 2020, The U.S. Food and Drug Administration (FDA) received a New Drug Application (NDA) for UPTRAVI (selexipag) as an intravenous (IV) injection to treat pulmonary arterial hypertension from Johnson & Johnson's Janssen Pharmaceutical Companies.
- In 2020, The Japanese Ministry of Health, Labour, and Welfare (MHLW) simultaneously approved new treatment options for Japanese patients, according to news released by Novartis Pharma K.K. ("Novartis Pharma"). For advanced and recurrent untreatable non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14) mutation, TabrectaTM (capmatinib, formerly INC280) is an oral MET inhibitor.
Global Pulmonary Drug Delivery Market Scope
The pulmonary drug delivery market is segmented on the basis of formulations, canister type, application, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Formulations
- Type
- Suspension aerosol
- Solution Aerosal
- Dry power formulation
- Device type
- Dry Powder Inhalers
- Single-Dose Inhalers
- Multi-Dose Inhaler
- Metered Dose Inhalers
- Manually-Actuated Pressurized Inhaler
- Breath-Actuated Pressurized Inhaler
- Nebulizers
- Jet Nebulizers
- Soft Mist Nebulizers
- Ultra Wave Nebulizers
- Mesh
- Vibrating
- Static
- Pneumatic
- Vented
- Breath Actuated
- Accessories
Canister Type
- Plain Canister
- Coated Canister
Application
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma
- Cystic Fibrosis
- Allergic Rhinitis
- Other
End-User
- Hospitals and Clinics
- Home Care Settings
Pulmonary Drug Delivery Market Regional Analysis/Insights
The pulmonary drug delivery market is analysed and market size insights and trends are provided by country, formulations, canister type, application, and end-user as referenced above.
The countries covered in the pulmonary drug delivery market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market due to the growing prevalence of respiratory and lung disorders, technological advancement, and increasing awareness. Furthermore, through an increase in the prevalence of pulmonary diseases, the presence of major players in the production and development of drugs for pulmonary diseases, an increase in the number of hospitals and diagnostic facilities, and government initiatives for treating pulmonary diseases in the area.
Asia-Pacific is expected to show a rapid and lucrative growth rate in the forecast period owing to Japan's increasing disposable and rising geriatric population. Moreover, the rising patient count with respiratory and acceptance of pulmonary drug devices will boost the region market, whereas increasing government initiatives to improve healthcare infrastructure will also expand market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Pulmonary Drug Delivery Market Share Analysis
The pulmonary drug delivery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pulmonary drug delivery market.
Some of the major players operating in the pulmonary drug delivery market are:
- F. Hoffmann-La Roche Ltd (Switzerland)
- MannKind Corporation (U.S.)
- OMRON Healthcare, Inc. (Japan)
- Mylan N.V (U.S.)
- 3M (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- Merck & Co., Inc., (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sunovion Pharmaceuticals Inc. (U.S.)
- PARI GmbH (Germany)
- Jabil Inc. (U.S.)
- AstraZeneca (U.K.)
- Boehringer Ingelheim International GmbH. (Germany)
- GSK plc. (U.K.)
- Novartis AG (Switzerland)
- Aerogen Pharma (Ireland)
- Briggs Healthcare (U.S.)
- HAAG-STREIT GROUP (Switzerland)
- Janssen Global Services, LLC (U.S.)
- AptarGroup, Inc. (U.S.)
SKU-